Home » Stocks » OCUL

Ocular Therapeutix, Inc. (OCUL)

Stock Price: $14.78 USD -0.46 (-3.02%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
After-hours: $14.71 -0.07 (-0.47%) Apr 20, 7:03 PM
Market Cap 1.14B
Revenue (ttm) 17.40M
Net Income (ttm) -155.64M
Shares Out 60.75M
EPS (ttm) -2.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $14.78
Previous Close $15.24
Change ($) -0.46
Change (%) -3.02%
Day's Open 15.16
Day's Range 14.62 - 15.45
Day's Volume 796,830
52-Week Range 4.76 - 24.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The biotech has a ways to go.

2 weeks ago - The Motley Fool

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -27.78% and -4.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

1 month ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therap...

1 month ago - Business Wire

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Ocular Therapeutix Inc (NASDAQ: OCUL) has dosed the first patient in its Phase 2 trial evaluating OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of the signs and...

1 month ago - Benzinga

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

1 month ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

1 month ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

1 month ago - Business Wire

Find out how shares of these disruptive businesses could make you rich.

Other stocks mentioned: CLOV, FLGT
2 months ago - The Motley Fool

There are a few reasons this could be the best biotech stock you can buy at the moment.

2 months ago - The Motley Fool

Ocular Therapeutix Inc (NASDAQ: OCUL) on Friday released limited data from its presentation on the ongoing Phase 1 trial evaluating OTX-TKI for wet age-related macular degeneration and other retinal dis...

Other stocks mentioned: AMD
2 months ago - Benzinga

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

2 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

2 months ago - Business Wire

Dextenza sales continue to grow despite the fact that COVID-19 cases are still continuing to rise. Recently, OCUL signed a deal to commercialize Dextenza and OTX-TIC internationally, proving the value o...

2 months ago - Seeking Alpha

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

3 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

3 months ago - Business Wire

Investors need to pay close attention to Ocular Therapeutix (OCUL) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

3 months ago - Business Wire

The FDA accepts Ocular's (OCUL) sNDA for label expansion of Dextenza to treat ocular itching associated with allergic conjunctivitis. The FDA will give its verdict in October 2021.

3 months ago - Zacks Investment Research

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

3 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

4 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

4 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapie...

4 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

5 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapie...

5 months ago - Business Wire

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 26.09% and 0.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 8.70% and 0.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

5 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

5 months ago - Business Wire

CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint recep...

Other stocks mentioned: CASI, INCY, ZLAB
5 months ago - Seeking Alpha

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

5 months ago - Business Wire

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

5 months ago - Business Wire

As of late, it has definitely been a great time to be an investor in Ocular Therapeutix (OCUL).

5 months ago - Zacks Investment Research

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

6 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

6 months ago - Business Wire

Ocular Therapeutix: Buy What 80% Of Patients Want

6 months ago - Seeking Alpha

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

6 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therap...

6 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

6 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

6 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc.

7 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc.

7 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc.

7 months ago - Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc.

7 months ago - Business Wire

Ocular - Small-Cap Pharmaceutical Growth Story

7 months ago - Seeking Alpha

Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -6.25% and -1.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

About OCUL

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an ax... [Read more...]

Industry
Biotechnology
IPO Date
Jul 25, 2014
CEO
Antony Mattessich
Employees
181
Stock Exchange
NASDAQ
Ticker Symbol
OCUL
Full Company Profile

Financial Performance

In 2020, OCUL's revenue was $17.40 million, an increase of 311.71% compared to the previous year's $4.23 million. Losses were -$155.64 million, 80.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for OCUL stock is "Buy." The 12-month stock price forecast is 25.50, which is an increase of 72.53% from the latest price.

Price Target
$25.50
(72.53% upside)
Analyst Consensus: Buy